“Nucleome Therapeutics, a pioneering UK-based biotech firm focused on decoding non-coding human genetics to address inflammatory diseases, has named Dr. Michelle Morrow as its new Chief Scientific Officer, effective February 23, 2026. With over two decades of experience in drug discovery, development, and R&D strategy across biotech and pharmaceutical sectors, Dr. Morrow brings proven expertise in immunology, oncology, and pharmacology to accelerate the company’s innovative pipeline targeting chronic inflammatory conditions through its breakthrough 3D genetics platform.”
Nucleome Therapeutics Appoints Dr. Michelle Morrow as Chief Scientific Officer
Nucleome Therapeutics continues to strengthen its executive team at a pivotal moment in its growth trajectory. The Oxford-headquartered company, which specializes in unraveling the molecular underpinnings of inflammatory diseases using a novel approach to 3D human genetics, announced the appointment of Dr. Michelle Morrow to the role of Chief Scientific Officer. She will assume her responsibilities on February 23, 2026.
Dr. Morrow arrives with an extensive background spanning more than 20 years in advancing therapeutic programs from early discovery through clinical stages. Her career has encompassed leadership positions in both emerging biotech ventures and major pharmaceutical organizations, where she has driven R&D strategies, built high-performing scientific teams, and successfully translated complex biological insights into viable drug candidates. Notably, she has deep domain knowledge in immunology and related fields, having previously held senior scientific roles that involved overseeing biology, translational sciences, and the progression of innovative oncology and immune-modulating therapies.
This strategic hire aligns closely with Nucleome’s mission to pioneer precision medicines by targeting the “dark matter” of the genome—non-coding regions that play critical roles in gene regulation but have historically been underexplored. The company’s proprietary platform integrates advanced functional genomics, multi-omic data integration, and 3D chromatin mapping to create a comprehensive atlas of immune system dysregulation derived directly from human disease genetics. This enables the identification of novel drug targets, mechanistic disease drivers, and patient stratification opportunities that traditional approaches often overlook.
In recent developments, Nucleome has demonstrated significant momentum. The company nominated its first preclinical development candidate earlier this year, a first-in-class monoclonal antibody agonist program designed to resolve inflammation. This asset, characterized by strong potency, selectivity, and developability, holds broad potential across major chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where unresolved inflammation drives persistent pathology.
The nomination underscores the productivity of Nucleome’s genetics-driven discovery engine, which has generated hundreds of potential targets by linking genetic variants to functional outcomes in immune cells. By focusing on inflammation resolution mechanisms rather than broad suppression, the approach aims to deliver safer, more durable therapies with improved efficacy profiles.
Dr. Morrow’s expertise is particularly well-suited to this phase. Her track record includes establishing preclinical modeling groups for immuno-oncology portfolios, leading bispecific antibody programs, and navigating the complexities of translating genetic and biological insights into actionable therapeutics. Her prior roles have involved close collaboration across multidisciplinary teams to advance candidates from hit identification through IND-enabling studies and into early clinical development.
The appointment comes as Nucleome builds on its foundation as a post-Series A biotechnology company with state-of-the-art facilities in Oxford. The firm maintains in-house capabilities for validating genetic findings through cutting-edge functional genomics, allowing rapid iteration between discovery and preclinical validation. This integrated model positions Nucleome to pursue both internal development and high-value pharmaceutical partnerships.
Industry observers note that the biotech sector increasingly values leaders who can bridge genetic insights with practical drug development. Dr. Morrow’s transition to Nucleome reflects growing confidence in the company’s platform and its potential to redefine treatment paradigms for inflammatory disorders, which affect millions worldwide and represent a substantial unmet medical need.
With this leadership enhancement, Nucleome is poised to accelerate its pipeline momentum, refine target selection, and advance its lead programs toward clinical candidacy. The addition of such seasoned expertise signals a clear intent to scale operations and deliver on the promise of genetics-informed precision medicine in immunology.
Disclaimer: This is a news report based on publicly available information. It is not investment advice, medical guidance, or a solicitation to buy or sell securities. Readers should conduct their own due diligence.